Market Cap 215.17B
Revenue (ttm) 46.79B
Net Income (ttm) 15.51B
EPS (ttm) N/A
PE Ratio 12.25
Forward PE 14.59
Profit Margin 33.14%
Debt to Equity Ratio 0.72
Volume 8,178,100
Avg Vol 11,709,802
Day's Range N/A - N/A
Shares Out 4.47B
Stochastic %K 5%
Beta 0.77
Analysts Hold
Price Target $47.28

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 45 44 44 88 88
Address:
Novo Alle 1, Bagsvaerd, Denmark
Richynr1
Richynr1 Jul. 24 at 1:39 PM
$NVO and wallstreet analysts still saying that LLY pill will outperform nvo 🤣👌
0 · Reply
texas__red
texas__red Jul. 24 at 1:38 PM
0 · Reply
Gergely_Blasko
Gergely_Blasko Jul. 24 at 1:19 PM
The week’s best $NVO news — the kind that should make the stock explode today. (Will $LLY sink?) IQVIA: Oral Wegovy prescriptions jumped 15.1% WoW to 169,781, versus just 26,761 for Lilly’s orforglipron at the same launch stage. Novo’s obesity pill is showing dramatically stronger early momentum. (ATH!!!) TRIUMPH-2 & 3: Retatrutide delivered 20.8% and 22.6% weight loss, well below the 28.3% headline from TRIUMPH-1. The supposedly overwhelming efficacy advantage over CagriSema now looks far less convincing — while Lilly’s FDA filing has slipped to Q1 2027 + Potential cardiovascular overhang: Retatrutide showed a numerical 12% increase in 3-point MACE vs placebo. Today’s legal escalation: Novo has expanded its action against Lilly by seeking a preliminary injunction to immediately block the disputed Mounjaro and Zepbound advertisements, alleging misleading dose comparisons and false superiority claims. Stronger commercial momentum, a narrowing efficacy gap, a delayed competitor...
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jul. 24 at 12:33 PM
0 · Reply
michele1208
michele1208 Jul. 24 at 12:11 PM
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 24 at 10:50 AM
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/novo-nordisk-reportedly-escalates-legal-battle-against-eli-lilly-even-as-analysts-see-lly-leading-the-glp-1-race/cZZYsGBR7y1
0 · Reply
mz08
mz08 Jul. 24 at 10:49 AM
$MNKD << FDA $LLY $NVO $PFE
0 · Reply
ChartExplorers
ChartExplorers Jul. 23 at 11:19 PM
0 · Reply
Abraham4329
Abraham4329 Jul. 23 at 9:14 PM
$LLY should publish Triumph papers, starting with Triumph 4 reported in Q3 2025. Arrhythmia rates need to settle. Not great for its reputation as a clean, top-tier pharma. $NVO should publish Redefine 4 too.
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 23 at 8:14 PM
$HIMS didnt they just copy $NVO products?
2 · Reply
Latest News on NVO
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

Fri, 24 Jul 2026 09:09:00 -0400 - 32 minutes ago

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize


Weight loss drugs linked to increase risk of hair loss

Jul 22, 2026, 8:57 PM EDT - 1 day ago

Weight loss drugs linked to increase risk of hair loss

LLY NVO


Novo Sues Rival Lilly Over Weight-Loss Ads

Jul 21, 2026, 10:21 AM EDT - 2 days ago

Novo Sues Rival Lilly Over Weight-Loss Ads

LLY NVO


Novo Nordisk wins EU approval for Wegovy weight-loss pill

Jul 15, 2026, 12:40 PM EDT - 8 days ago

Novo Nordisk wins EU approval for Wegovy weight-loss pill

NVO


Novo Nordisk announces updated semaglutide label in Singapore

2026-07-08T09:20:10.000Z - 16 days ago

Novo Nordisk announces updated semaglutide label in Singapore


Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 5 weeks ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN LLY TWST


The Next Phase Of The Obesity Drug Race

Jun 13, 2026, 2:00 PM EDT - 5 weeks ago

The Next Phase Of The Obesity Drug Race

GPCR LLY


Novo Nordisk hit by cyber incident, probes data breach

Jun 11, 2026, 11:45 AM EDT - 6 weeks ago

Novo Nordisk hit by cyber incident, probes data breach


Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.

Jun 11, 2026, 11:42 AM EDT - 6 weeks ago

Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.


Novo Nordisk A/S: IT Security incident at Novo Nordisk

Jun 11, 2026, 11:30 AM EDT - 6 weeks ago

Novo Nordisk A/S: IT Security incident at Novo Nordisk


UK health regulator approves Novo Nordisk's weight-loss pill

Jun 11, 2026, 11:01 AM EDT - 6 weeks ago

UK health regulator approves Novo Nordisk's weight-loss pill


Novo Nordisk CEO: We are a cardiometabolic powerhouse

Jun 9, 2026, 1:30 PM EDT - 6 weeks ago

Novo Nordisk CEO: We are a cardiometabolic powerhouse


Use of GLP-1 drugs early in pregnancy should not cause alarm

Jun 8, 2026, 5:05 PM EDT - 6 weeks ago

Use of GLP-1 drugs early in pregnancy should not cause alarm

LLY


Richynr1
Richynr1 Jul. 24 at 1:39 PM
$NVO and wallstreet analysts still saying that LLY pill will outperform nvo 🤣👌
0 · Reply
texas__red
texas__red Jul. 24 at 1:38 PM
0 · Reply
Gergely_Blasko
Gergely_Blasko Jul. 24 at 1:19 PM
The week’s best $NVO news — the kind that should make the stock explode today. (Will $LLY sink?) IQVIA: Oral Wegovy prescriptions jumped 15.1% WoW to 169,781, versus just 26,761 for Lilly’s orforglipron at the same launch stage. Novo’s obesity pill is showing dramatically stronger early momentum. (ATH!!!) TRIUMPH-2 & 3: Retatrutide delivered 20.8% and 22.6% weight loss, well below the 28.3% headline from TRIUMPH-1. The supposedly overwhelming efficacy advantage over CagriSema now looks far less convincing — while Lilly’s FDA filing has slipped to Q1 2027 + Potential cardiovascular overhang: Retatrutide showed a numerical 12% increase in 3-point MACE vs placebo. Today’s legal escalation: Novo has expanded its action against Lilly by seeking a preliminary injunction to immediately block the disputed Mounjaro and Zepbound advertisements, alleging misleading dose comparisons and false superiority claims. Stronger commercial momentum, a narrowing efficacy gap, a delayed competitor...
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jul. 24 at 12:33 PM
0 · Reply
michele1208
michele1208 Jul. 24 at 12:11 PM
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 24 at 10:50 AM
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/novo-nordisk-reportedly-escalates-legal-battle-against-eli-lilly-even-as-analysts-see-lly-leading-the-glp-1-race/cZZYsGBR7y1
0 · Reply
mz08
mz08 Jul. 24 at 10:49 AM
$MNKD << FDA $LLY $NVO $PFE
0 · Reply
ChartExplorers
ChartExplorers Jul. 23 at 11:19 PM
0 · Reply
Abraham4329
Abraham4329 Jul. 23 at 9:14 PM
$LLY should publish Triumph papers, starting with Triumph 4 reported in Q3 2025. Arrhythmia rates need to settle. Not great for its reputation as a clean, top-tier pharma. $NVO should publish Redefine 4 too.
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 23 at 8:14 PM
$HIMS didnt they just copy $NVO products?
2 · Reply
GSTX7
GSTX7 Jul. 23 at 8:02 PM
$NVO Dumped this from my portfolio. Tired of looking at it.
2 · Reply
IntrinsicTrader
IntrinsicTrader Jul. 23 at 7:02 PM
$LLY $NVO Same bro IDK why LLY is up and recovers every single day.
0 · Reply
JohnnyVacs
JohnnyVacs Jul. 23 at 6:57 PM
$VKTX It is. It’s called they aren’t selling and thats all anyone wants here. Funny how all other GLP-1 other than $KLRA are doing just fine today. $LLY $NVO $GPCR all perfectly fine. This drop is VIKING SPECIFIC and will continue to drop back to $30 with the CLOWN🤡 CEO in charge. This stock is easy. Buy at $30 and sell high $30’s. Rinse repeat. Brian Lian is a disaster to this company business wise. Wait till he sells shares in a couple days. Then it drops even more.
0 · Reply
Gergely_Blasko
Gergely_Blasko Jul. 23 at 5:41 PM
$LLY $NVO One more thing the market shouldn't ignore: Retatrutide showed a numerical 12% increase in 3-point MACE vs placebo in today's Phase 3 update. The dataset was too small for firm conclusions, so this is not evidence of cardiovascular harm. But it is enough to raise an important question that future CV data will need to answer. When you combine: - lower-than-hoped efficacy in the new trials, - a Q1 2027 filing timeline, - and now a potential CV overhang, the "untouchable next-generation winner" narrative looks a lot less certain than it did yesterday.
1 · Reply
Gergely_Blasko
Gergely_Blasko Jul. 23 at 5:36 PM
Today's $LLY update is more important for $NVO than many realize. Two key takeaways: - Retatrutide's new Phase 3 results ( Triumph-2 and -3: 20.8% and 22.6% weight loss) were notably below the blockbuster 28.3% headline from TRIUMPH-1. The "30%+ in every population" narrative is fading. - Lilly now targets Q1 2027 for its FDA filing (instead of second half of 2026), pushing commercialization further out than many investors had expected. Why this matters for $NVO: - Longer runway for Wegovy and CagriSema. - Less pressure from a supposedly game-changing next-generation competitor. - The efficacy gap between CagriSema and retatrutide now looks much narrower than the market previously assumed. The market had priced retatrutide as an overwhelming leap forward. Today's data suggest the competitive landscape may be more balanced than that narrative implied.
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 23 at 5:32 PM
Healthcare may be due for a pullback after the strong rally of the past two months. My outlook on 4 key names: $NVO Next target: ~$31 I expect $NVO to potentially break below its current low of $35.12. Around that area, the stock could complete its correction and set up for a future bullish reversal. $HIMS Next target: $50+ The only healthcare name I remain bullish on. As long as $HIMS holds above the $21.53 support level, the long-term bullish thesis remains intact. $OSCR Next target: at least $21 I expect $OSCR could pull back into the $21-$15 target zone before the broader bullish trend potentially resumes. $UNH Next target: $211 $UNH may finish its current rebound before facing another downside move below the previous low of $234.37. Short-term corrections are normal. The key is identifying where risk/reward becomes attractive. Follow my page for more technical analysis, healthcare stocks, and market setups.
3 · Reply
Bug1
Bug1 Jul. 23 at 5:23 PM
$NVO Houston we encountered a new kind of bot!
1 · Reply
LunkerInvesting
LunkerInvesting Jul. 23 at 5:15 PM
$NVO crazy hims has been a better investment 😂
1 · Reply
Pseudominds
Pseudominds Jul. 23 at 4:56 PM
$NVO retatrutide will not destroy novo, it will destroy tirzepitide. Essentially cannibalizing its own pipeline. What is there to destroy when novo injectable pipeline is already beaten up by lily’s lesser drug? Thats like saying; iPhone 17 will destroy the flip phone market 😂. iPhone 17 will destroy iPhone 16 market is the truth. Now on the other hand, novo oral pills is much more superior and all the sales data is proving it. :)
1 · Reply
Austinhilton
Austinhilton Jul. 23 at 4:53 PM
Healthcare is about to roll over—and I think it will surprise a lot of people. After the strong rally we've seen over the past two months, I expect most of the healthcare sector to enter a corrective phase. My outlook for 4 key names: 1. $NVO Next target: ~$31 I expect $NVO to make new lows below its current low of $35.12. Around that area, I expect the stock to complete its correction and begin a bullish trend reversal. 2. $HIMS Next target: $50+ The only healthcare stock I'm currently bullish on. As long as we don't see a break below the red line at $21.53, I remain bullish. 3. $OSCR Next target: at least $21 I expect $OSCR to decline into a target zone between $21 and $15. From there, I expect the long-term bullish trend to resume. 4. $UNH Next target: $211 I expect $UNH to complete its current upward move soon before falling below its previous low of $234.37, with a downside target of at least $211.
3 · Reply
Hooooooold
Hooooooold Jul. 23 at 4:25 PM
$NVO green on red day. Niceeee
1 · Reply